Natural peripheral vision

To introduce new technology for the design of innovative intraocular lenses (iols) that fully restore natural peripheral vision for motion detection, significantly improving quality of life of yearly millions of cataract patients with an iol implant.

Cataract is the leading cause of blindness worldwide (39%, World Health Organisation, 2010). Every year over 15 million people worldwide have cataract surgery performed. When a patient undergoes cataract surgery, the cataractous lens is removed and replaced with a prosthetic lens known as an intraocular lens (IOL). Current technology IOLs restore central vision adequately, however, it has been discovered recently that the image quality in the peripheral field of view is significantly reduced by current IOLs. This is a result of the fact that peripheral vision has never been considered in IOL technology. This has potential implications for everyday tasks, especially those requiring motion detection, such as walking and car driving, manoeuvring in low light conditions, participating in sports with an inherent increase of incidences like falls and fractures. Therefore, improving peripheral vision obtained with IOLs will significantly increase postoperative quality of life. The aim of the Natural Peripheral Vision project is to acquire the knowledge necessary to introduce new technology for the design of innovative intraocular lenses that fully restores peripheral vision, significantly improving the quality of life of millions of people having an IOL implanted. The topic of restoring peripheral vision for IOL patients is complex and has many interdisciplinary and multidisciplinary aspects. This will be managed using a multi-centre approach, in which experts in ophthalmology, optics, vision science and clinical research merge their knowledge and capabilities to solving the issue of pseudophakic peripheral vision. A central step in this project is to quantify, compare, and understand how peripheral refractive error and aberration influence patients' peripheral vision. This will enable an optimisation of the processes used in the optical design of intraocular lenses, thereby restoring natural peripheral vision. The project includes optical measurements, psychophysical measurements, as well as measurement of ocular geometry (high field MRI imaging). The results of these three approaches all tie together into the development of new IOL technology. The project will be carried out through the collaboration between six partners, each having their specific expertise and capabilities in this field of research. The MRI Gorter Center and Ophthalmology Department at LEIDEN UNIVERSITY MEDICAL CENTRE (LUMC) in The Netherland, and the Ophthalmology Department of the UNIVERSITY OF ROSTOCK (ROSTOCK) in Germany are world leaders in high field MRI imaging. VOPTICA S.L. in Murcia (VOPTICA) in Spain, and Laboratorio de Optica of the UNIVERSITY OF MURCIA (LOUM) in Spain are world leaders in vision research and vision simulation. The VIENNA INSTITUTE FOR RESEARCH IN OCULAR SURGERY (VIROS) of the Hanusch Hospital Vienna in Austria is a leading centre in clinical research. AMO GRONINGEN B.V. (AMO) in The Netherlands will be the pivotal research centre, specialised in IOL research, development and lens manufacturing technology. the facility is the global centre for IOL activities of ABBOTT MEDICAL OPTICS, a division within Abbott Inc. AMO GRONINGEN B.V. is recognised as an innovator in the growing global market for advanced IOL technology, and has a wide experience in leading and coordinating international research and development projects. The knowledge of the partners complements each other very well. To illustrate this, the knowledge of the partners of interest to this project is: * ROSTOCK: MRI imaging and MRI technology (world leader); * LUMC: Ophthalmic and MRI imaging facilities; the same patient could be measured for anatomical and optical properties and a paired comparison can be made; * VOPTICA: Technical and clinical functionality of clinical diagnostics; * LOUM: Extensive knowledge of peripheral aberrations; * VIROS: Extensive experience in testing novel IOL devices; * AMO: Combine outcomes of all of the above into new IOL technology. The advantage of this consortium and its knowledge is, that it combines first class technology partners with all the knowledge that is needed to make the next-generation innovation of this project possible and NPV-IOLs achievable within a three year period.
Project ID: 
7 187
Start date: 
Project Duration: 
Project costs: 
2 700 000.00€
Technological Area: 
Medical technology
Market Area: 
Other medical/health related (not elsewhere classified)

Raising the productivity and competitiveness of European businesses through technology. Boosting national economies on the international market, and strengthening the basis for sustainable prosperity and employment.